Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Feb 2022
Historique:
received: 13 01 2022
revised: 16 02 2022
accepted: 21 02 2022
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Inherited cardiomyopathy caused by the p.(Arg14del) pathogenic variant of the phospholamban (

Identifiants

pubmed: 35269571
pii: ijms23052427
doi: 10.3390/ijms23052427
pmc: PMC8909937
pii:
doi:

Substances chimiques

Calcium-Binding Proteins 0
Oligonucleotides, Antisense 0
Protein Aggregates 0
phospholamban 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Netherlands Heart Institute
ID : 2020B005 (DCVA-DOUBLE-DOSE)
Organisme : Netherlands Heart Institute
ID : 2018-30 (CVON-PREDICT2)
Organisme : Netherlands Heart Institute
ID : 2017-21 (CVON-SHE-PREDICTS-HF)
Organisme : Netherlands Heart Institute
ID : 2017-11 (CVON-RED-CVD)
Organisme : Netherlands Heart Institute
ID : 2014-40 (CVON-DOSIS)
Organisme : Leducq Foundation
ID : Cure PhosphoLambaN-induced cardiomyopathy (CURE-PLaN)
Organisme : European Research Council
ID : Consolidator Grant (CoG) 818715 (SECRETE-HF)
Pays : International

Références

J Clin Med. 2020 Jun 26;9(6):
pubmed: 32604776
J Mol Cell Cardiol. 2016 Nov;100:1-8
pubmed: 27642167
Histopathology. 2016 Oct;69(4):542-50
pubmed: 26970417
Int J Mol Sci. 2021 Apr 23;22(9):
pubmed: 33922643
Nat Rev Mol Cell Biol. 2003 Jul;4(7):566-77
pubmed: 12838339
Sci Rep. 2019 Dec 10;9(1):18765
pubmed: 31822739
Sci Rep. 2020 Jun 17;10(1):9819
pubmed: 32555305
Trends Cell Biol. 2014 Sep;24(9):506-14
pubmed: 24946960
Circulation. 2019 Oct;140(14):1188-1204
pubmed: 31567019
Int J Mol Sci. 2020 Sep 04;21(18):
pubmed: 32899712
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1388-93
pubmed: 16432188
Cardiovasc Res. 2021 Jul 27;117(9):2108-2124
pubmed: 32871009
Circ Res. 1994 Sep;75(3):401-9
pubmed: 8062415
J Mol Biol. 2007 Mar 16;367(1):65-79
pubmed: 17241641
Am J Physiol Heart Circ Physiol. 2019 Jun 1;316(6):H1552-H1557
pubmed: 30978120
Eur J Heart Fail. 2012 Nov;14(11):1199-207
pubmed: 22820313
Circulation. 1995 Aug 15;92(4):778-84
pubmed: 7641356
Circulation. 2018 Aug 14;138(7):678-691
pubmed: 29459363
J Mol Cell Cardiol. 2018 Oct;123:185-197
pubmed: 30261161
Int J Mol Sci. 2017 Oct 25;18(11):
pubmed: 29068413
Int J Mol Sci. 2021 Nov 02;22(21):
pubmed: 34769334
Int J Mol Sci. 2021 Dec 16;22(24):
pubmed: 34948294
Nat Rev Mol Cell Biol. 2013 Jan;14(1):55-61
pubmed: 23258296
Neth Heart J. 2022 Feb;30(2):84-95
pubmed: 34143416
Theranostics. 2018 Jul 30;8(15):4155-4169
pubmed: 30128044
Circ Heart Fail. 2021 Nov;14(11):e008532
pubmed: 34587756
Amyloid. 2016 Jun;23(2):109-18
pubmed: 27033334
PLoS One. 2013 Sep 06;8(9):e72651
pubmed: 24039788
J Clin Invest. 2003 Mar;111(6):869-76
pubmed: 12639993
Cell Mol Biol Lett. 2016 Dec 13;21:29
pubmed: 28536631
Circulation. 2021 Aug 3;144(5):382-392
pubmed: 33928785
Nat Rev Cardiol. 2020 May;17(5):286-297
pubmed: 31605094
Circ Res. 2001 Jul 6;89(1):84-91
pubmed: 11440982
Int J Mol Sci. 2021 Mar 14;22(6):
pubmed: 33799487
Circ Heart Fail. 2021 Jan;14(1):e007684
pubmed: 33356362
Cardiovasc Pathol. 2017 Sep - Oct;30:23-26
pubmed: 28759816
Int J Mol Sci. 2017 Aug 28;18(9):
pubmed: 28846632
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Trends Cardiovasc Med. 2020 Aug;30(6):353-361
pubmed: 31585768
Nat Commun. 2021 Aug 30;12(1):5180
pubmed: 34462437
Autophagy. 2011 Mar;7(3):279-96
pubmed: 21189453
EMBO Mol Med. 2021 Jun 7;13(6):e13074
pubmed: 33998164
Cardiovasc Res. 2021 Jan 1;117(1):43-59
pubmed: 32365197

Auteurs

Tim R Eijgenraam (TR)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Nienke M Stege (NM)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Vivian Oliveira Nunes Teixeira (V)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Remco de Brouwer (R)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Netherlands Heart Institute, Moreelsepark 1, 3511 EP Utrecht, The Netherlands.

Elisabeth M Schouten (EM)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Niels Grote Beverborg (N)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Liu Sun (L)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Daniela Später (D)

Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 50 Gothenburg, Sweden.

Ralph Knöll (R)

Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 50 Gothenburg, Sweden.

Kenny M Hansson (KM)

Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 50 Gothenburg, Sweden.

Carl Amilon (C)

Projects, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 50 Gothenburg, Sweden.

David Janzén (D)

Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 50 Gothenburg, Sweden.

Steve T Yeh (ST)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Adam E Mullick (AE)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Peter van der Meer (P)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Rudolf A de Boer (RA)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Herman H W Silljé (HHW)

University Medical Center Groningen, Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH